Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
Zacks' 7 Best Stocks
for June, 2013
FREE Report for Zacks.com
Visitors Only
Visitors Only
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
- Latest News
- Most Popular
- 3 Top-Ranked Consumer ETFs to Buy Now
- This Week's Top Value Stocks
- RTI: When Will We Finally See a Pullback?
- RTI: When is the Fed's "Taper Telegraph" Coming?
- Insurance Industry Stock Outlook - May 2013
- Top Stocks with Big Potential Catch-Up Moves
- Roundtable Top Picks of the Week
- Anatomy of Success: Green Mountain Coffee
- The Mega-Rally Rolls On
- Biotechnology ETF Investing 101
- AWS 5/21: The Beginning of the End for QE
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/21/2013
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
The CropScience unit of Bayer ( BAYRY - Analyst Report ) recently announced that it has inked a deal to buy the watermelon and melon seed business of the US based privately-held seed company, Abbott & Cobb Inc. The financial terms of the deal, expected to close shortly, were not revealed. The transaction, following its closure, should strengthen the vegetable seed business at Bayer.
We note that Abbott & Cobb is a key player in the market for watermelons in the US. Moreover, the company operates in Mexico, Australia and Asia. Through this acquisition, Bayer aims to strengthen its presence in the promising Asian market.
The move is consistent with Bayer’s focus on emerging markets. Sales in these markets improved by 9% on an adjusted basis to €13,290 million in 2011. Emerging markets accounted for 36.4% of total revenues in 2011. The comparable figure in 2010 was 35.6%. Sales from emerging markets were encouraging in the first quarter of 2012 as well, improving 6%.
With factors like pricing pressure and intensifying generic competition affecting sales in large pharmaceutical markets, companies are looking towards emerging markets to drive growth.
The CropScience segment is one of the world's leading crop-science companies in the area of crop protection, non-agricultural pest control, seeds, and plant biotechnology. It develops and markets chemical crop protection products (insecticides, herbicides, and fungicides), seeds, and integrated plant biotechnology solutions for agricultural and non-agricultural uses.
Even though impressed by the expansion efforts of Bayer, we expect investor focus to remain on the performance of blood-thinner Xarelto for the lucrative stroke prevention in nonvalvular atrial fibrillation (SPAF) indication (approved late last year). Bayer’s efforts to expand the label of Xarelto into additional indications are encouraging. The HealthCare unit of Bayer has co-developed Xarelto with the Janssen Research and Development unit of Johnson & Johnson ( JNJ - Analyst Report ) .
Our Recommendation
We currently have a Neutral recommendation on Bayer in the long-run. The company carries a Zacks #3 Rank (Hold rating) in the short-run.
Read the full Analyst Report on BAYRY
Read the full Analyst Report on JNJ